Rhumbline Advisers Novavax Inc Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Novavax Inc stock. As of the latest transaction made, Rhumbline Advisers holds 208,464 shares of NVAX stock, worth $1.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

208,464

Previous 195,440 6.66%

Holding current value

$1.76 Million

Previous $2.47 Million 32.09%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	BUY	$7.22 - $14.68 $94,033 - $191,192	13,024 Added 6.66%	208,464 $1.68 Million
Q3 2024 Nov 12, 2024	SELL	$10.71 - $17.11 $47,862 - $76,464	-4,469 Reduced 2.24%	195,440 $2.47 Million
Q2 2024 Aug 01, 2024	BUY	$3.89 - $20.97 $219,100 - $1.18 Million	56,324 Added 39.23%	199,909 $2.53 Million
Q1 2024 May 09, 2024	BUY	$3.76 - $6.02 $48,522 - $77,688	12,905 Added 9.88%	143,585 $686,000
Q4 2023 Feb 08, 2024	BUY	$4.8 - $7.67 $31,382 - $50,146	6,538 Added 5.27%	130,680 $627,000
Q3 2023 Nov 09, 2023	BUY	$6.81 - $9.74 $5,679 - $8,123	834 Added 0.68%	124,142 $898,000
Q2 2023 Aug 08, 2023	BUY	$6.67 - $9.52 $168,317 - $240,237	25,235 Added 25.73%	123,308 $916,000
Q1 2023 May 11, 2023	BUY	$5.76 - $12.48 $92,476 - $200,366	16,055 Added 19.57%	98,073 $680,000
Q4 2022 Feb 14, 2023	SELL	$8.86 - $25.04 $97 - $275	-11 Reduced 0.01%	82,018 $843,000
Q3 2022 Nov 10, 2022	BUY	$18.2 - $76.12 $38,201 - $159,775	2,099 Added 2.63%	82,029 $1.49 Million
Q2 2022 Aug 11, 2022	BUY	$36.28 - $75.29 $278,557 - $578,076	7,678 Added 10.63%	79,930 $4.11 Million
Q1 2022 May 12, 2022	SELL	$69.73 - $142.9 $437,207 - $895,983	-6,270 Reduced 7.99%	72,252 $5.32 Million
Q4 2021 Feb 10, 2022	BUY	$134.56 - $217.97 $572,014 - $926,590	4,251 Added 5.72%	78,522 $11.2 Million
Q3 2021 Nov 12, 2021	SELL	$177.8 - $270.58 $172,999 - $263,274	-973 Reduced 1.29%	74,271 $15.4 Million
Q2 2021 Aug 05, 2021	SELL	$121.0 - $257.67 $2.65 Million - $5.64 Million	-21,870 Reduced 22.52%	75,244 $16 Million
Q1 2021 May 06, 2021	SELL	$112.98 - $319.93 $495,304 - $1.4 Million	-4,384 Reduced 4.32%	97,114 $17.6 Million
Q4 2020 Feb 10, 2021	BUY	$78.74 - $139.5 $663,620 - $1.18 Million	8,428 Added 9.06%	101,498 $11.3 Million
Q3 2020 Nov 12, 2020	SELL	$79.44 - $178.51 $1.16 Million - $2.61 Million	-14,639 Reduced 13.59%	93,070 $10.1 Million
Q2 2020 Aug 13, 2020	BUY	$13.86 - $83.61 $812,376 - $4.9 Million	58,613 Added 119.38%	107,709 $8.98 Million
Q1 2020 May 06, 2020	BUY	$3.93 - $16.0 $62,872 - $255,968	15,998 Added 48.34%	49,096 $667,000
Q4 2019 Feb 05, 2020	SELL	$3.69 - $5.22 $1,217 - $1,722	-330 Reduced 0.99%	33,098 $132,000
Q3 2019 Oct 23, 2019	BUY	$4.02 - $7.84 $12,534 - $24,445	3,118 Added 10.29%	33,428 $168,000
Q2 2019 Aug 14, 2019	BUY	$4.93 - $12.2 $149,428 - $369,782	30,310 New	30,310 $178,000

Others Institutions Holding NVAX

# of Institutions

288

Shares Held

94.7M

Call Options Held

6.95M

Put Options Held

9.4M

View Full List

About NOVAVAX INC

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $659M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

More about NVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Novavax Inc Transaction History